Increased adrenergic tone resulting from cardiovascular stress leads to development of heart failure, in part, through chronic stimulation of b1 adrenergic receptors (bARs) on cardiac myocytes. Blocking these receptors is part of the basis for b-blocker therapy for heart failure. Recent data demonstrate that G protein-coupled receptors (GPCRs), including bARs, are activated intracellularly, although the biological significance is unclear. Here we investigated the functional role of Golgi bARs in cardiac myocytes and found they activate Golgi localized, prohypertrophic, phosphoinositide hydrolysis, that is not accessed by cell surface bAR stimulation. This pathway is accessed by the physiological neurotransmitter norepinephrine (NE) via an Oct3 organic cation transporter. Blockade of Oct3 or specific blockade of Golgi resident b1ARs prevents NE dependent cardiac myocyte hypertrophy. This clearly defines a physiological pathway activated by internal GPCRs in a biologically relevant cell type and has implications for development of more efficacious b-blocker therapies.
Introduction
Cardiovascular disease, particularly heart failure, is the leading cause of disease and death in the developed world. In response to long term pathological stress, such as hypertension or myocardial infarction, the levels of neurohumoral factors such as epinephrine, endothelin and angiotensin II increase. These hormones directly stimulate G protein-coupled receptors (GPCRs), including b-adrenergic receptors in cardiac myocytes (1) (2) (3) . Chronic stimulation of these receptors, including stimulation of badrenergic receptors (bARs) by catecholamines, drives cardiac hypertrophy and ventricular remodeling, ultimately leading to heart failure. The efficacy of b-blocker therapy for treatment of heart failure results, at least in part, by ameliorating chronic bAR stimulation in the heart (4, 5) .
Previous studies by our group, and others, have implicated specific phospholipase C (PLC) enzymes downstream of Gq and Gs-coupled GPCRs in the regulation of cardiac hypertrophy. PLCb isoforms stimulated by Gq have been implicated in cardiac hypertrophy driven by cell surface a-adrenergic receptors (aAR) (6, 7) . Our laboratory identified a critical role of PLCe in cardiac hypertrophy driven downstream of the endothelin (ET-1A) receptor and cAMP signaling by bARs (8, 9) . PLCe is poised as a nexus for multiple receptor signaling systems due its diversity of upstream regulators including heterotrimeric G protein bg subunits and small GTPases, including Rap, Rho and Ras, and cAMP via the Rap guanine nucleotide exchange factor (GEF), Epac (10) (11) (12) (13) (14) .
PLCe and Epac are scaffolded together at the nuclear envelope in cardiac myocytes by the hypertrophic organizer, muscle-specific A kinase anchoring protein (mAKAPb), in close proximity to the Golgi apparatus (15) . Activation of PLCe in cardiac myocytes induces hydrolysis of phosphatidylinositol-4-phosphate (PI4P) at the Golgi apparatus leading to release of diacylglycerol (DAG) and inactive IP2 in the vicinity of the nucleus to facilitate nuclear protein kinase D (PKD) and subsequent downstream hypertrophic pathways (9, 16) . In previous work we found that either the Epac-selective cAMP analog, cpTOME, or forskolin stimulation of adenylate cyclase, activate PLCedependent Golgi PI4P hydrolysis in cardiac myocytes. Surprisingly, the bAR agonist isoproterenol (Iso), does not stimulate Golgi PI4P hydrolysis despite strongly stimulating cAMP production (8, 9) . As an explanation for this apparent paradox we demonstrated PLCe-dependent PI4P hydrolysis can be controlled by two distinct pools of cAMP delimited by distinct PDE isoforms. One pool, limited by PDE3 acts through Epac and Rap1 to activate PLCe, while a second pool controlled by PDE2 and/or PDE9A inhibits PLCe activity through activation of PKA (17) . cAMP generated downstream of Iso cannot access the Epac/mAKAPb/PLCe complex unless PDE3 is specifically inhibited partially explaining the lack of activation of Golgi PI4P hydrolysis by Iso.
5
A new paradigm for generating localized cAMP signals in cells has been established by a number of recent studies indicating that GPCRs in different intracellular compartments have discrete signaling outputs (18) (19) (20) (21) (22) . An emergent idea is that bARs internalized into endosomes continue to stimulate cAMP accumulation resulting in cellular outcomes distinct from those generated by bARs at the cell surface. Irannejad et al established that b1ARs expressed at the Golgi apparatus in HeLa cells can induce G protein activation in the Golgi when stimulated by either a cell permeant agonist, dobutamine, through passive diffusion, or the physiological hormone epinephrine, when transported across the cell membrane by the organic cation transporter, Oct3 (19) . These ideas led us to hypothesize that in cardiac myocytes, bARs resident at the Golgi apparatus could generate cAMP that has privileged access to the Epac/mAKAPb/PLCe scaffold at the nuclear envelope/Golgi interface, thereby yielding a set of signals divergent from those generated by cell surface bARs. We demonstrate that endogenous b1ARs at the Golgi apparatus in cardiac myocytes are required to stimulate hypertrophic Epac/PLCe-dependent PI4P hydrolysis at the Golgi, and that these intracellular bARs can be accessed by physiological neurotransmitters, and synthetic b-blockers and agonists.
These data present a potential new paradigm for drug development for treating heart failure through deliberate targeting of internal bARs in cardiac myocytes.
Results

Dobutamine induces b1-AR activation and PI4P hydrolysis at the Golgi.
In previous studies we showed that cAMP produced upon stimulation with the bAR agonist, Iso, does not induce PI4P hydrolysis at the Golgi in NRVMs without addition of a PDE3 inhibitor (17) . We hypothesized that intracellular bARs may be required to generate a specific pool of cAMP with privileged access to the Epac/mAKAPb/PLCe complex, and that the cell impermeant agonist, Iso, is unable to access these internal receptors. To test this hypothesis, we utilized the membrane permeant b1AR-agonist, dobutamine, either alone, or in combination with the bAR antagonists, metoprolol and sotalol, which are membrane-permeant and -impermeant, respectively (19) . NRVMs were transduced with an adenovirus expressing the PI4P biosensor, FAPP-PH-GFP and stimulated with dobutamine (100 nM) or PBS. In contrast to Iso, dobutamine stimulated rapid and sustained PI4P hydrolysis (Fig. 1A, left) . Addition of metoprolol, but not sotalol, blocked dobutamine-stimulated PI4P hydrolysis (Fig. 1A middle and right panels) . This indicates that stimulation of an intracellular population bARs is required for dobutamine-mediated PI4P hydrolysis. To visualize bAR activation at the Golgi apparatus, NRVMs transfected with translocatable Venus-based sensor of Gs coupled receptor activation, NES-Venusmini-Gs (23) . When a Gs coupled receptor is activated, NES-Venus-mini-Gs binds to the activated receptor, which is then visualized as translocation from the cytoplasm to membranes where the activated receptor is located providing information on receptor activation in subcellular compartments. In unstimulated cells NES-Venus-mini-Gs is distributed throughout the cytoplasm. We did not detect translocation of fluorescence to 7 endogenously expressed receptors (data not shown), so NRVMs were cotransfected with the b1AR. Addition of dobutamine to cells co-expressing NES-Venus-mini-Gs and b1AR, caused a rapid clearance of cytoplasmic fluorescence and accumulated fluorescence at the PM and punctate structures likely corresponding to nascent t-tubules. This was followed by slower translocation of Venus associated fluorescence to the perinuclear region of the cell colocalizing with the CFP-giantin, a marker for the Golgi apparatus (Fig. 1B, D and E and Movie S1). Iso also caused rapid translocation to the PM and t-tubules but, in contrast to dobutamine, no accumulation at the perinuclear region was observed ( Brefeldin A treatment significantly reversed NES-Venus-mini-Gs association with the perinuclear region, confirming Golgi localization of NES-Venus-mini-Gs ( Fig. S1 and Movie S3). Taken together, these data support the idea that a population of bARs present at the Golgi can be activated by exogenous agonists and stimulate Gs, ultimately resulting in PLC activation and PI4P hydrolysis.
PI4P hydrolysis by dobutamine requires Golgi-localized PLCe and Epac.
Previous data from our laboratory demonstrated that the Epac/mAKAPb/PLCe complex is responsible for cAMP-mediated PI4P hydrolysis at the Golgi in NRVMs (9, 17) . To determine if this complex is responsible for dobutamine stimulated PI4P hydrolysis we utilized adenoviral shRNA to deplete PLCe, or adenoviral transduction of the RA1 domain of PLCe, which competes for the interaction between PLCe and mAKAPb, disrupting the mAKAPb-PLCe complex (8) . PLCe shRNA depletion of PLCe completely inhibited PI4P hydrolysis stimulated by dobutamine, while control scrambled shRNA had no effect ( Fig.   2A ). Viral expression of the PLCe RA1 domain also inhibited PI4P hydrolysis stimulated by dobutamine (Fig. 2B) . This demonstrates that mAKAPb-scaffolded PLCe is required for dobutamine-mediated PI4P hydrolysis. The Epac-selective inhibitor HJC0726 inhibited PI4P hydrolysis stimulated by dobutamine (Fig. 2C) , however, the bg inhibitor Gallein had no effect (Fig. 2D) . Taken together, these data indicate that Golgi PI4P hydrolysis stimulated by intracellular GPCRs requires the Epac/mAKAPb/PLCe complex.
Inhibition of Golgi bARs prevents PI4P hydrolysis stimulated by dobutamine
The data presented so far suggest that dobutamine acts through bARs at the Golgi apparatus to stimulate Golgi PI4P hydrolysis. To more directly demonstrate a requirement for endogenous bAR activation in the Golgi we targeted the bAR selective nanobody, Nb80, to the Golgi apparatus using the rapamycin inducible FRB-FKBP system. This approach has been previously used to inhibit bARs at the Golgi in Hela cells (19) . NRVMs were transduced with virus containing CFP-Nb80-FRB and FKBP-mAppleGalT protein for Golgi targeting along with a virus expressing GFP-FAPP-PH. Cells were selected that were positive for mApple and CFP (Fig. 3A) , and GFP fluorescence. In cells pretreated with vehicle control, dobutamine stimulated PI4P hydrolysis. However, following addition of 1µM Rapamycin, dobutamine-induced PI4P hydrolysis was significantly inhibited (Fig. 3B ). These data confirm that bARs expressed directly on the Golgi are required for dobutamine-mediated PI4P hydrolysis at the Golgi.
Nb80 can bind to and block both b1 and b2ARs and while dobutamine is relatively selective for b1ARs over b2ARs, it can still potentially stimulate b2ARs. To confirm that dobutamine stimulated PI4P hydrolysis is through b1ARs, cells were treated with the cell permeant highly selective b1AR antagonist CGP-20172 (100nM) followed by stimulation with dobutamine.
CGP-20172 completely blocked dobutamine-stimulated PI4P hydrolysis ( Fig. 3C ), indicating that the dobutamine stimulation of Golgi localized PI4P
hydrolysis is through Golgi localized b1ARs.
Norepinephrine (NE) induces PI4P hydrolysis and bAR activation at internal membranes in cardiac myocytes.
Thus far we have shown that the synthetic b1AR selective agonist, dobutamine can enter cells, activate intracellular bARs, and stimulate intracellular PLC activity which has interesting pharmacological implications but may not be relevant to physiological cardiac regulation. For this reason, we determined if the sympathetic neurotransmitter norepinephrine (NE) could stimulate PI4P hydrolysis, and bAR activation at the Golgi in NRVMs. Cells transduced with adenovirus containing FAPP-PH-GFP were stimulated with NE (10 µM) at 37 o C. NE caused delayed, but robust and sustained PI4P hydrolysis bARs. To further determine if NE could enter cells and activate bARs at the Golgi, we monitored NES-Venus-mini-Gs recruitment to the Golgi in response to NE. NE initially stimulated NES-Venus-mini-Gs translocation to the plasma membrane as was observed for dobutamine, followed by slower, NES-Venus-mini-Gs translocation to the Golgi ( Fig.   4B and Movie S4). Thus, NE enters cardiac myocytes, accesses internal bARs, and stimulates PI4P hydrolysis.
Inhibition of the membrane cation transporter, OCT3, prevents norepinephrine induced PI4P hydrolysis.
Data from other laboratories has demonstrated that transport of norepinephrine or epinephrine into cells by organic cation transporter family of proteins (OCT proteins) is required for activation of internal receptors in adult cardiac myocytes (24) and HELA cells (19) . The non-selective cation transporter, OCT3 has been shown to be responsible for this transport, therefore we utilized three structurally distinct inhibitors of OCT3, corticosterone (100 µM, Preincubation of NRVMs with any of these inhibitors prevented NE from inducing PI4P
hydrolysis, suggesting that OCT3-mediated transport is required for PI4P hydrolysis by this catecholamine. In addition, we sought to determine if receptor internalization is required for NE-mediated PI4P hydrolysis and bAR activation at the Golgi. An inhibitor of dynamin-mediated receptor internalization, Dyngo (40 µM), had no effect on either PI4P hydrolysis (Fig. 5D ) or recruitment of NES-Venus-mini-Gs to the Golgi membrane ( Fig. 5E and Movie S5) by norepinephrine. Corticosterone (100µM) had no effect on dobutamine-mediated PI4P hydrolysis (data not shown). These data indicate that agonist transport by OCT transporters, not receptor internalization, is required for NE-mediated
Golgi bAR activation and PI4P hydrolysis.
Additionally, NRVMs were transduced with viruses containing FRB-CFP-Nb80 and FKBP-mApple-GalT, along with FAPP-PH-GFP to determine if Golgi b1AR were required for PI4P hydrolysis to NE. In cells pretreated with vehicle, norepinephrine induces PI4P
hydrolysis. However, following addition of 1µM Rapamycin, norepinephrine-induced PI4P hydrolysis was significantly inhibited (Fig. 5F ).
To confirm that dobutamine and NE stimulated Golgi PI4P hydrolysis is not unique to neonatal myocytes we tested the ability of dobutamine and NE to stimulate PI4P 
Cardiac hypertrophy induced by dobutamine is more effectively inhibited by a cell permeant antagonist.
To determine if signaling by internal bARs is important for promotion of cellular hypertrophy, NRVMs were treated with dobutamine (100 nM) for 48 h and two measures of hypertrophy were assessed, cell area and ANF expression. Dobutamine stimulated an increase cell area (Fig. 7A) , and ANF expression (Fig. 7B) , after 48 hours of stimulation.
Co-incubation with the cell permeant antagonist, metoprolol, strongly inhibited these hypertrophic responses. The cell impermeant antagonist, sotalol, on the other hand was significantly less effective at blocking these hypertrophy measures than metoprolol, ( Fig.   7A and B), but did have a small effect on changes in cell area. These data, taken together with PI4P hydrolysis data, suggest that internal bARs are involved in mediating cardiomyocyte hypertrophy.
Golgi bARs and agonist internalization are required for stimulation of NRVM hypertrophy
by NE. NE is an endogenously produced catecholamine involved in mediating hypertrophy and heart failure and stimulation of NRVMs with NE stimulates hypertrophy.
To determine the role of intracellular NE in hypertrophy, NRVMs were treated with NE in the presence or absence of Corticosterone to block Oct3 cation transporters for 48h.
Treatment with NE stimulated an increase in cell size (Fig. 8A ) and ANF expression ( Fig.   8B ) that was blocked by Corticosterone indicating that transport of NE into the myocyte is required to mediate hypertrophy. Treatment with dobutamine also induced hypertrophy 13 but this was not blocked by Oct3 supporting the idea that dobutamine access to internal receptors does not require Oct3 and confirms the specificity of the Oct3 blockade.
To determine if NE and dobutamine driven NRVM hypertrophy requires Golgi bARs NRVMs were transduced with adenovirus containing CFP-Nb80-FRB and FKBPmApple-GalT for 24 h followed by treatment for 48h with NE or dobutamine with and without co-treatment with rapamycin. In the absence of rapamycin, NE and dobutamine stimulated increases in cell area and ANF expression ( Fig. 8C and D) . Co-treatment with rapamycin to translocate Nb80 to the Golgi blocked NE and dobutamine stimulated hypertrophy, demonstrating that Golgi bARs are required for stimulation of hypertrophy by these agonists.
Discussion
We previously found that raising cAMP levels with forskolin in NRVMs stimulated PI4P
hydrolysis, but Iso did not unless a specific PDE, PDE3 was blocked. This led to the question of how the Epac/mAKAPb/PLCe complex could be activated during physiological cAMP regulation by Gs coupled receptors. We considered two potential mechanisms, one where chronic agonist exposure alters the organization of PDEs in the cardiac myocyte such that Epac could be accessed by global cAMP changes, or that intracellular bARs generate cAMP with privileged access to the Epac/mAKAPb/PLCe complex. Here we demonstrate that stimulation of Golgi resident b1ARs induces Epac-PLCe-dependent PI4P hydrolysis when stimulated by either a membrane permeant drug, dobutamine, or the physiological neurotransmitter, norepinephrine. We also show that stimulation of these internal receptors is required for both dobutamine and NE stimulated cardiomyocyte hypertrophy.
Compartmentalized GPCR signaling
It is well established the GPCRs can be found on intracellular compartments (26) . 
The requirement of internal receptors for cardiac hypertrophy
Significantly, stimulation of hypertrophy by the natural sympathetic ligand NE required activity of Golgi localized bARs. As has been discussed, sustained elevated sympathetic drive is one of the major factors responsible for development of cardiac hypertrophy due to chronic hypertension. b-blocker therapy efficacy is thought to result from preventing chronic stimulation of cell surface bARs by elevated catecholamines and subsequent desensitization (4). Our results suggest that blockade of internal receptors may be required to prevent catecholamine-induced hypertrophy and demonstrates that activation of cell surface GPCRs is not sufficient for natural catecholamines to induce hypertrophy in NRVMs. The importance of blockade of Golgi GPCRs is supported by the fact that the cell permeant bAR antagonist metoprolol is significantly more effective than the cell impermeant antagonist sotalol in prevention of dobutamine stimulated cardiomyocyte hypertrophy. Interestingly, clinically effective b-blockers tend to be relatively hydrophobic.
Metoprolol and carvedilol are first line b blockers that are used to treat heart failure and have log P values 1.8 and 4.2 respectively, and are thus relatively cell permeant. Sotalol, which has a log P of -0.85 is relatively cell impermeant, and is not clinically used for heart failure treatment. We speculate that hydrophobicity might be an important factor for bblocker development allowing these inhibitors to access internal pools of receptor.
A seeming contradiction is the observation that the cell impermeant agonist isoproterenol induces hypertrophy in vitro and when chronically administered in vivo. Iso administered in vivo is not at physiological concentrations and has multiple target tissues beyond the cardiac myocyte, such as the vasculature, that could contribute to hypertrophy. For NRVMs in vitro, while Iso can induce hypertrophy by a mechanism that probably does not rely on internal receptors, the effects of the natural ligands epinephrine and norepinephrine are more relevant to the in vivo situation and do rely on Golgi localized bARs. The synthetic agonist Iso seems to rely on an alternative PM mediated pathway that is not engaged by the physiological agonist NE. It will be critical to determine if in the in vivo pathology of heart failure that internal b receptors play a critical role using animal models such as TAC that mimic hypertensive stress.
Materials and methods
Isolation of neonatal cardiac myocytes and adenoviral transduction
Briefly, hearts were excised from 2 to 4 day old Sprague-Dawley rats, ventricles separated and minced thoroughly before digestion with Collagen type II (Worthington) in 
NES-Venus-mini-Gs imaging
NRVMs were plated into gelatin-coated 20 mm glass bottom cell culture dishes. Cells were transfected the following day with plasmids (500-800 ng of b1-ARs and 250-400 ng of NES-Venus-mini-Gs per dish) using lipofectamine 3000. Media was changed to 1%
FBS the next day and transduced with adenovirus-expressing CFP-Giantin overnight.
Cells were imaged in confocal mode with a Leica DMi8 equipped with a Crest-optics Xlight V2 confocal unit and a 100x 1.4 NA oil-immersion lens. Venus was excited at 515
with an X-Cite Xled1 light source, and emission monitored imaged on a backlit CMOS Photometrics Prime 95B camera.
Measurement of PI4P hydrolysis
Measurements of PI4P hydrolysis were made as previously described (9, 11, 17) . After Other supplementary materials for this manuscript include the following:
Movies S1 to S5 Fig. S1 . Disruption of the Golgi apparatus reverses mini-Gs protein recruitment to the perinuclear region by dobutamine. NRVMs were transfected with β1-AR and NES-Venus-mini-Gs, followed by viral transduction with CFP-Giantin. Representative images of dobutamine-mediated NES-Venus-mini-Gs recruitment (100 nM, Upper panels) and CFP-Giantin Golgi marker (lower panels). Dobutamine was added at 2 min and Brefeldin A (5µg/ml), was added at 8 min just after the 8 min image above was captured. NES-Venus-mini-Gs recruitment continually monitored.
Movie S1. Dobutamine activates β1ARs in the Golgi apparatus. Confocal images of β1-ARs-overexpressing cardiomyocytes with NES-Venus-mini-Gs, treated with 100 nM dobutamine. Total time represented by the movie is 10 min and pictures were taken every 15 seconds. Dobutamine was added at 2 min timepoint.
Movie S2. Isoproterenol does not activate β1ARs in the Golgi apparatus.
Confocal images of β1-ARs-overexpressing cardiomyocytes with NES-Venusmini-Gs, treated with 100 nM isoproterenol. Total time represented by the movie is 10 min and pictures were taken every 15 seconds. Isoproterenol was added at 2 min timepoint.
Movie S3. Disruption of the Golgi apparatus inhibits activation of β1ARs in the Golgi apparatus. Reversal of mini Gs recruitment to Golgi membrane after addition of Brefeldin A. Total time represented by the movie is 30 min and pictures were taken every 30 seconds. Dobutamine was added at 2 min timepoint for 8 min and then Brefeldin A was added for next 20 min.
Movie S4. Norepinephrine activates β1ARs in the Golgi apparatus. Confocal images of β1-ARs-overexpressing cardiomyocytes with NES-Venus-mini-Gs, treated with 10 µM norepinephrine. Total time represented by the movie is 30 min and pictures were taken every 30 seconds. Norepinephrine was added at 2 min timepoint.
Movie S5. Inhibition of receptor internalization does not alter activation of β1ARs in the Golgi apparatus. Confocal images of β1-ARs-overexpressing cardiomyocytes with NES-Venus-mini-Gs, pretreated with 40 µM Dyngo. Total time represented by the movie is 30 min and pictures were taken every 30 seconds. Dyngo was added 15 min prior to experimentation and norepinephrine was added at 2 min timepoint.
